id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_56vcqxxymzemha3rjfsu3otz3i	Jonathan C. Cohen	APOC3, Coronary Disease, and Complexities of Mendelian Randomization	2014.0	3	.pdf	application/pdf	2183	220	64	Two new studies report that triglyceride (TG)-lowering mutations in APOC3 reduce coronary heart disease Here, we explore limitations of using Mendelian randomization to evaluate CHD risk, including potential confounding by the widespread use of statin therapy. that were associated with a 39% reduction in plasma TG levels (Crosby et al., association with CHD in 110,097 individuals from 15 different studies. (A) Reduction in CHD risk associated with genetic variants (blue circles) and pharmacological agents are associated with a greater reduction in CHD compared to that seen in statin trials. represents the CHD reduction (�46%) that is predicted for a loss-of-function mutation in APOC3 (B) Effects of APOC3 loss-of-function variants on circulating lipid and lipoprotein levels and on CHD. A factor that may mask the contribution of plasma LDL-C levels to the reduction in CHD in APOC3 carriers is statin effects of LDL-C on CHD risk and the association between APOC3 mutations	./cache/work_56vcqxxymzemha3rjfsu3otz3i.pdf	./txt/work_56vcqxxymzemha3rjfsu3otz3i.txt